Telomir Pharmaceuticals (NASDAQ: TELO) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer (TNBC). The clearance allows the company to initiate a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing, and preliminary antitumor activity. The trial is supported by preclinical pharmacology, toxicology, and biomarker data as Telomir advances its lead candidate toward clinical development.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Its lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The FDA clearance marks a significant milestone for Telomir, as TNBC is an aggressive subtype of breast cancer that lacks targeted therapies and has a poor prognosis. The Phase 1/2 trial will assess the drug's potential to address this unmet medical need. If successful, Telomir-Zn could offer a new treatment option for patients with advanced or metastatic TNBC.
"Receiving FDA IND clearance is a critical step in our mission to develop innovative therapies for patients with limited options," said a company spokesperson. "We are eager to begin the clinical trial and gather data on Telomir-Zn's safety and efficacy."
The news is particularly important for the biotechnology and oncology sectors, as TNBC represents a high-need area where current treatments are often ineffective. Telomir's approach, targeting epigenetic and metabolic pathways, could provide a novel mechanism of action that differentiates it from existing therapies. For investors, the IND clearance reduces regulatory risk and signals progress toward potential commercialization. The company's focus on metal homeostasis and redox balance also opens possibilities for broader applications in aging and degenerative diseases.
For more details, the full press release is available at https://ibn.fm/p4e9J. Additional updates on Telomir Pharmaceuticals can be found in the company's newsroom at https://ibn.fm/TELO.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company, and the IND clearance moves it into clinical-stage development. The upcoming trial will be closely watched by the medical and investment communities for signs of efficacy and safety in TNBC patients.
